BUDGET IMPACT OF ORAL PROLONGED-RELEASE FAMPRIDINE FOR MANAGEMENT OF WALKING DISABILITY ASSOCIATED WITH MULTIPLE SCLEROSIS IN TAIWAN

被引：0
|
作者：
Lee-Grossman, C. W. [1 ]
Alexopoulos, S. T. [2 ]
Murphy, D. R. [2 ]
机构：
[1] Biogen Idec Inc, Weston, ACT, Australia
[2] Heron Evidence Dev Ltd, Luton, Beds, England
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A675 / A676
页数：2
相关论文
共 50 条
  • [21] Do Cerebellar Symptoms Predict Treatment Response to Prolonged-Release Fampridine in Multiple Sclerosis Patients?
    Siva, Aksel
    Limmroth, Volker
    Potts, James
    Putzki, Norman
    Goodman, Andrew
    NEUROLOGY, 2012, 78
  • [22] Prolonged-release fampridine treatment and walking ability and balance in patients with multiple sclerosis: results of the randomized, double-blind MOBILE study
    Mehta, L. R.
    Lycke, J.
    Short, C.
    Gasperini, C.
    Hupperts, R.
    McNeill, M.
    Medori, R.
    Elkins, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 192 - 192
  • [23] Treatment patterns and costs among patients with multiple sclerosis treated with prolonged-release fampridine in Germany
    Lee, A.
    Liu, Y.
    Gleissner, E.
    Prosser, C.
    Kinter, E.
    Landsman-Blumberg, P.
    Braun, S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 670 - 670
  • [24] Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial
    Hupperts, Raymond
    Lycke, Jan
    Short, Christine
    Gasperini, Claudio
    McNeill, Manjit
    Medori, Rossella
    Tofil-Kaluza, Agata
    Hovenden, Maria
    Mehta, Lahar R.
    Elkins, Jacob
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (02) : 212 - 221
  • [25] Prolonged-Release Fampridine Treatment and Walking Ability and Balance in Patients with Multiple Sclerosis: Results of the Randomized, Double-Blind MOBILE Study
    Lycke, Jan
    Short, Christine
    Gasperini, Claudio
    Hupperts, Raymond
    McNeil, Manjit
    Medori, Rossella
    Mehta, Lahar
    Elkins, Jacob
    NEUROLOGY, 2014, 83 (02) : E36 - E36
  • [26] Prolonged-Release Fampridine Induces Sustained Clinically Meaningful Improvements in Walking Ability in People with Multiple Sclerosis: Results from the ENHANCE Trial
    Hobart, Jeremy
    Ziemssen, Tjalf
    Feys, Peter
    Linnebank, Michael
    Goodman, Andrew
    Farrell, Rachel
    Englishby, Veronica
    McNeill, Manjit
    Chang, Ih
    Mehta, Lahar
    Elkins, Jacob
    NEUROLOGY, 2017, 88
  • [27] Prolonged-release fampridine treatment and walking ability and balance in patients with multiple sclerosis: results of the randomized, double-blind MOBILE study
    Mehta, L. R.
    Lycke, J.
    Short, C.
    Gasperini, C.
    Hupperts, R.
    McNeill, M.
    Medori, R.
    Elkins, J.
    JOURNAL OF NEUROLOGY, 2014, 261 : S134 - S134
  • [28] Prolonged-release fampridine shows consistent efficacy across sub-groups of multiple sclerosis patients
    Stourac, P.
    Putzki, N.
    JOURNAL OF NEUROLOGY, 2012, 259 : S152 - S153
  • [29] Multiple sclerosis patients concurrently treated with disease-modifying therapies show clinically meaningful increases in walking speed with prolonged-release fampridine
    Kieseier, B.
    Schapiro, R.
    Goodman, A.
    Putzki, N.
    JOURNAL OF NEUROLOGY, 2011, 258 : 261 - 261
  • [30] Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine
    Sola-Valls, Nuria
    Blanco, Yolanda
    Sepulveda, Maria
    Llufriu, Sara
    Martinez-Lapiscina, Elena H.
    Zubizarreta, Irati
    Pulido-Valdeolivas, Irene
    Montejo, Carmen
    Villoslada, Pablo
    Saiz, Albert
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
12345